GB2510587B - Biospecific agents for bone - Google Patents

Biospecific agents for bone Download PDF

Info

Publication number
GB2510587B
GB2510587B GB1302199.3A GB201302199A GB2510587B GB 2510587 B GB2510587 B GB 2510587B GB 201302199 A GB201302199 A GB 201302199A GB 2510587 B GB2510587 B GB 2510587B
Authority
GB
United Kingdom
Prior art keywords
bone
biospecific agents
biospecific
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1302199.3A
Other languages
English (en)
Other versions
GB201302199D0 (en
GB2510587A (en
Inventor
Santin Matteo
Thomas Meikle Steven
Mbundi Lubinda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orthopaedic Research UK
Original Assignee
Orthopaedic Research UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthopaedic Research UK filed Critical Orthopaedic Research UK
Priority to GB1302199.3A priority Critical patent/GB2510587B/en
Publication of GB201302199D0 publication Critical patent/GB201302199D0/en
Priority to US14/765,508 priority patent/US20150367000A1/en
Priority to JP2015556563A priority patent/JP6400026B2/ja
Priority to HK16105926.0A priority patent/HK1217910B/en
Priority to CN201480007874.8A priority patent/CN105142729A/zh
Priority to PCT/GB2014/050265 priority patent/WO2014122431A1/en
Priority to ES14702931T priority patent/ES2904260T3/es
Priority to NZ710436A priority patent/NZ710436A/en
Priority to EP14702931.8A priority patent/EP2953682B1/en
Priority to CA2898366A priority patent/CA2898366C/en
Publication of GB2510587A publication Critical patent/GB2510587A/en
Priority to JP2018153482A priority patent/JP6683773B2/ja
Priority to US16/693,780 priority patent/US11464878B2/en
Application granted granted Critical
Publication of GB2510587B publication Critical patent/GB2510587B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Pulmonology (AREA)
  • Theoretical Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Signal Processing (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
GB1302199.3A 2013-02-07 2013-02-07 Biospecific agents for bone Expired - Fee Related GB2510587B (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GB1302199.3A GB2510587B (en) 2013-02-07 2013-02-07 Biospecific agents for bone
ES14702931T ES2904260T3 (es) 2013-02-07 2014-01-31 Agentes biospecíficos para huesos
EP14702931.8A EP2953682B1 (en) 2013-02-07 2014-01-31 Biospecific agents for bone
HK16105926.0A HK1217910B (en) 2013-02-07 2014-01-31 Biospecific agents for bone
CN201480007874.8A CN105142729A (zh) 2013-02-07 2014-01-31 骨生物特异性试剂
PCT/GB2014/050265 WO2014122431A1 (en) 2013-02-07 2014-01-31 Biospecific agents for bone
US14/765,508 US20150367000A1 (en) 2013-02-07 2014-01-31 Biospecific agents for bone
NZ710436A NZ710436A (en) 2013-02-07 2014-01-31 Biospecific agents for bone
JP2015556563A JP6400026B2 (ja) 2013-02-07 2014-01-31 骨のための生体特異的な薬剤
CA2898366A CA2898366C (en) 2013-02-07 2014-01-31 Biospecific agents for bone
JP2018153482A JP6683773B2 (ja) 2013-02-07 2018-08-17 骨のための生体特異的な薬剤
US16/693,780 US11464878B2 (en) 2013-02-07 2019-11-25 Biospecific agents for bone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1302199.3A GB2510587B (en) 2013-02-07 2013-02-07 Biospecific agents for bone

Publications (3)

Publication Number Publication Date
GB201302199D0 GB201302199D0 (en) 2013-03-27
GB2510587A GB2510587A (en) 2014-08-13
GB2510587B true GB2510587B (en) 2020-05-20

Family

ID=47998779

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1302199.3A Expired - Fee Related GB2510587B (en) 2013-02-07 2013-02-07 Biospecific agents for bone

Country Status (9)

Country Link
US (2) US20150367000A1 (enExample)
EP (1) EP2953682B1 (enExample)
JP (2) JP6400026B2 (enExample)
CN (1) CN105142729A (enExample)
CA (1) CA2898366C (enExample)
ES (1) ES2904260T3 (enExample)
GB (1) GB2510587B (enExample)
NZ (1) NZ710436A (enExample)
WO (1) WO2014122431A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3226905T (pt) 2014-02-27 2022-01-19 Synartro Ab Conjugados de hialuronano com substâncias farmaceuticamente ativas, métodos e composições
JP7156665B2 (ja) * 2017-06-13 2022-10-19 国立研究開発法人量子科学技術研究開発機構 医薬、並びにその製造方法
CN108187143A (zh) * 2018-02-09 2018-06-22 福州大学 一种兼具磁热效应和原位诱导成骨的多功能复合材料及其制备方法
CN109289119B (zh) * 2018-09-16 2022-05-17 华北理工大学 一种用于脊柱康复系统的磁性纳米粒子球混合物
US11944982B2 (en) 2019-06-05 2024-04-02 Battelle Memorial Institute Polymer-functionalized magnetic particle embodiments for solute separation, and devices and systems for using the same
CN111558041A (zh) * 2020-04-30 2020-08-21 浙江理工大学 羟基磷灰石包裹磁性载药纳米颗粒及其制备方法和在制备骨肉瘤光疗药物中的应用
WO2023041639A2 (fr) * 2021-09-15 2023-03-23 Centre National De La Recherche Scientifique Nanoparticules hybrides
CN117582485B (zh) * 2023-11-15 2024-06-07 湛江中心人民医院 方格星虫三肽在制备骨质疏松药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206146A1 (en) * 2005-03-21 2008-08-28 Massoud Akhtari Functionalized Magnetic Nanoparticles and Methods of Use Thereof
US20100301855A1 (en) * 2009-05-29 2010-12-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, methods, and compositions including targeted ferromagnetic structures
AU2012204100A1 (en) * 2005-03-21 2012-08-02 The Regents Of The University Of California Functionalized magnetic nanoparticles and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
WO2003072593A2 (en) * 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
JP4833862B2 (ja) * 2004-01-28 2011-12-07 サイトイミューン サイエンシズ インコーポレイテッド 官能化コロイド金属組成物および方法
AU2006294578B2 (en) * 2005-09-28 2013-02-07 The Regents Of The University Of California Calcium binding peptides
US20100028387A1 (en) * 2007-06-12 2010-02-04 Ganesan Balasundaram Biocompatible Coated Nanostructured Titanium Surfaces
US9316645B2 (en) * 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206146A1 (en) * 2005-03-21 2008-08-28 Massoud Akhtari Functionalized Magnetic Nanoparticles and Methods of Use Thereof
AU2012204100A1 (en) * 2005-03-21 2012-08-02 The Regents Of The University Of California Functionalized magnetic nanoparticles and methods of use thereof
US20100301855A1 (en) * 2009-05-29 2010-12-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, methods, and compositions including targeted ferromagnetic structures

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Invest Radiol; Vol 38, pp 750-760 (2003). Alves et al. "Silencing of phosphonate-gadolinium magnetic resonance imaging contrast by hydroxyapatite binding" *
J Osteoporosis; Vol 2010, pp 747852 (2010). Lalatonne et al. "Superparamagnetic bifunctional bisphosphonates nanoparticles: a potential MRI contrast agent for osteoporosis therapy and diagnostic" *
Nanoscale; Vol 2, pp 582-586 (2010). Zhang et al. "Preparation of functionalized gold nanoparticles as a targeted X-ray contrast agent for damaged bone tissue" *
Organ Biomol Chem; Vol 4, pp 3611-3617 (2006). Parkesh et al. "Synthesis and evaluation of potential CT agents for bone structure and microdamage analysis" *
Semin Muskoskelet Radiol; Vol 13, pp 145-156 (2009). Daldrup-Link et al. "New perspectives on bone marrow contrast agents and molecular imaging" *

Also Published As

Publication number Publication date
NZ710436A (en) 2020-07-31
WO2014122431A1 (en) 2014-08-14
CA2898366A1 (en) 2014-08-14
JP2018199693A (ja) 2018-12-20
US20150367000A1 (en) 2015-12-24
US11464878B2 (en) 2022-10-11
US20200215207A1 (en) 2020-07-09
CN105142729A (zh) 2015-12-09
EP2953682A1 (en) 2015-12-16
GB201302199D0 (en) 2013-03-27
EP2953682B1 (en) 2021-10-13
JP2016509007A (ja) 2016-03-24
ES2904260T3 (es) 2022-04-04
HK1217910A1 (zh) 2017-01-27
JP6683773B2 (ja) 2020-04-22
JP6400026B2 (ja) 2018-10-03
GB2510587A (en) 2014-08-13
CA2898366C (en) 2021-05-04

Similar Documents

Publication Publication Date Title
IL266651B (en) graft
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
AU352451S (en) Sterilizer
GB201321739D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321744D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321732D0 (en) Therapeutic agents
GB201321737D0 (en) Therapeutic Agents
GB2583032B (en) Components for medical circuits
GB201321748D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201302199D0 (en) Biospecific agents for bone
GB201321731D0 (en) Therapeutic agents
EP2932931A4 (en) SURGERY SYSTEM

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20250207